每經AI快(kuai)訊，華(hua)(hua)東(dong)(dong)醫藥(yao)(yao)10月10日晚間發(fa)布公(gong)(gong)告稱，近日，華(hua)(hua)東(dong)(dong)醫藥(yao)(yao)股份有(you)限公(gong)(gong)司全資(zi)子公(gong)(gong)司杭州中美(mei)(mei)華(hua)(hua)東(dong)(dong)制藥(yao)(yao)有(you)限公(gong)(gong)司和杭州中美(mei)(mei)華(hua)(hua)東(dong)(dong)制藥(yao)(yao)江東(dong)(dong)有(you)限公(gong)(gong)司收到國家藥(yao)(yao)品(pin)監督管理(li)局（NMPA）核準簽(qian)發(fa)的(de)《藥(yao)(yao)物臨(lin)床試(shi)驗批(pi)準通知書》，由(you)中美(mei)(mei)華(hua)(hua)東(dong)(dong)和江東(dong)(dong)公(gong)(gong)司共同申報的(de)司美(mei)(mei)格魯肽注(zhu)射液臨(lin)床試(shi)驗申請獲得(de)批(pi)準。

每經頭(tou)條（nbdtoutiao）——

(記者 王曉波)

免責聲明：本文內容與(yu)數(shu)據(ju)僅供參(can)考，不構成投資建議，使用前請核實。據(ju)此操作，風(feng)險自擔。